Orphan Drug Developer Ultragenyx Licenses Kyowa Hakko Kirin’s X-Linked Hypophosphataemia Drug
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 9 (Table of Contents)
Published: 10 Sep-2013
DOI: 10.3833/pdr.v2013.i9.1977 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Orphan drug specialist Ultragenyx Pharmaceuticals, which was founded in 2010 and raised US$75 M in a Series B equity financing in December 2012, has signed its second licensing deal of 2013...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS